SOUTHBOROUGH, Mass.--(BUSINESS WIRE)--Veristat, the Science-First Full Service CRO and Consultancy, announced an appointment to its executive leadership team. Rachel Page joins Veristat as Chief Commercial Officer (CCO), succeeding Veristat’s longtime leader Cindy Henderson, who recently transitioned to become Chief Strategy Officer (CSO) to focus on developing and executing Veristat’s customer-driven corporate strategy..

马萨诸塞州SOUTHBOROUGH。-（商业新闻短讯）--Veristat，科学第一家全方位服务的首席风险官和咨询公司，宣布任命其执行领导团队。瑞秋·佩奇（Rachel Page）接替Veristat的长期领导辛迪·亨德森（Cindy Henderson），加入Veristat担任首席商务官（CCO），辛迪·亨德森最近转任首席战略官（CSO），专注于开发和执行Veristat的客户驱动型企业战略。。

With over two decades of experience in global health and science commercialization, Rachel is poised to energize our brand and leverage our deep industry expertise. Her role will be crucial in assisting biopharmaceutical companies as they navigate their most complex clinical and regulatory challenges to speed the delivery of innovative therapies..

凭借20多年的全球健康和科学商业化经验，Rachel准备为我们的品牌注入活力，并利用我们深厚的行业专业知识。她的角色对于帮助生物制药公司应对最复杂的临床和监管挑战以加速创新疗法的提供至关重要。。

“Veristat has a 30-year history of driving innovative approaches that help deliver what are often breakthrough therapies to patients in need,” stated Patrick Flanagan, Chief Executive Officer. “Rachel’s accomplishments and experience empowering people, building commercial organizations, and fostering trusted client relationships demonstrate her ability to successfully lead the execution of our strategic plan.

首席执行官帕特里克·弗拉纳根（PatrickFlanagan）表示：“Veristat在推动创新方法方面有30年的历史，这些方法可以帮助为有需要的患者提供突破性的治疗方法。”。“Rachel的成就和经验赋予了人们权力，建立了商业组织，培养了值得信赖的客户关系，证明了她有能力成功领导我们战略计划的执行。

Rachel has received tremendous recognition for her unwavering commitment to client success. I am confident in her ability to leverage Veristat’s deep industry experience on a global scale.”.

Rachel因其对客户成功的坚定不移的承诺而获得了极大的认可。我相信她有能力在全球范围内利用Veristat丰富的行业经验。”。

Rachel’s extensive global network and her successful history in all phases of the pharmaceutical lifecycle will be instrumental in delivering impactful results for our clients.

Rachel广泛的全球网络和她在药物生命周期各个阶段的成功历史将有助于为我们的客户提供有影响力的结果。

'I am thrilled to join this dynamic, science-driven team,' Rachel commented. 'Veristat is exceptional at facilitating the delivery of crucial therapies and transforming client operations. I am honored to collaborate with such a passionate group of executives, colleagues, and clients who are dedicated to accelerating the availability of groundbreaking treatments for patients with complex conditions.

“我很高兴加入这个充满活力、科学驱动的团队，”雷切尔评论道Veristat在促进关键疗法的提供和改变客户操作方面表现出色。我很荣幸能与一群充满激情的高管、同事和客户合作，他们致力于加速为患有复杂疾病的患者提供开创性的治疗。

I am eager to lead our talented global commercial team and contribute to achieving our clients’ vital objectives.'.

我渴望领导我们才华横溢的全球商业团队，为实现客户的重要目标做出贡献。”。

In her new role, Rachel will oversee Veristat’s commercialization strategy and operations, including business development, proposals, contracts, marketing, and fostering robust client relationships. She will also focus on the growth and development of the commercial team, ensuring continued success in meeting our clients’ needs..

在她的新角色中，Rachel将监督Veristat的商业化战略和运营，包括业务开发、提案、合同、营销和培养强大的客户关系。她还将专注于商业团队的成长和发展，确保在满足客户需求方面取得持续成功。。

About Veristat

关于Veristat

Veristat is the Science-First CRO™ and Consultancy that integrates full service clinical trial execution, regulatory affairs and safety, and strategic advisor services to rapidly advance the development, approval, and commercialization of novel therapies (#NovelTherapies) around the globe. With 30 years of experience solving sponsors' unique and complex clinical, statistical, and regulatory challenges, Veristat Science-First experts deliver timely, quality-driven results with solutions that are tailored to the needs of patients, clinical trial sites, regulators, sponsor teams, and key stakeholders..

Veristat是Science First CRO™和咨询公司，它集成了全方位服务的临床试验执行、监管事务和安全以及战略顾问服务，以快速推进全球新型疗法（#NovelTherapies）的开发、批准和商业化。凭借30年解决赞助商独特而复杂的临床，统计和监管挑战的经验，Veristat Science First专家通过针对患者，临床试验地点，监管机构，赞助商团队和关键利益相关者的需求量身定制的解决方案，提供及时，质量驱动的结果。。

Veristat's focus on novel drug development has led to success when handling any unknown that arises, from the simplest to most complex, across numerous therapeutic areas including rare/ultra-rare disease, advanced therapies, oncology, and biologics including cell and gene therapies (#cellandgenetherapy), enabling sponsors to succeed in extending and saving patients’ lives.

Veristat专注于新药开发，在众多治疗领域（包括罕见/超罕见疾病，先进疗法，肿瘤学和生物制剂，包括细胞和基因疗法（#cellandgenetherapy））处理从最简单到最复杂的任何未知问题时取得了成功，使赞助商能够成功地延长和挽救患者的生命。

Sponsors collaborate with Veristat Science-First experts who care— like they do. It is not just business for Veristat, it’s personal..

赞助商与Veristat Science的第一批关心他们的专家合作。这不仅是Veristat的业务，也是个人事务。。